Gilead, GSK, and Pfizer Leaders to Headline Bioprocessing Summit 2026 Plenary on AI in Quality

Industry
โดย PR Newswire·Read original
Summary · why it matters

Leaders from Gilead Sciences, GSK, and Pfizer will headline the opening plenary of the 18th Annual Bioprocessing Summit in Boston this August, exploring how AI and digital technologies are reshaping biopharmaceutical quality. The plenary presentation, delivered by Anthony Mire-Sluis, Senior Vice President of Global Quality at Gilead Sciences, will focus on practical strategies for integrating digital technologies and AI into quality organizations while maintaining scientific rigor and regulatory compliance. A subsequent fireside chat moderated by Susan Hynes, Global Head of Quality at GSK, will feature Mire-Sluis alongside Lynn Bottone, Senior Vice President of Quality Operations, Environment, Health & Safety at Pfizer, discussing regulatory expectations and organizational readiness. The Summit, taking place August 10-13, 2026, will bring together 1,000 scientists, engineers, and technology innovators across 12 conference tracks and more than 300 scientific presentations.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 3 stocks
Gilead Sciences Inc
GILD
± MixedTechnologyrelevance

Gilead's quality leader is presenting at a conference on AI in bioprocessing, but no specific business impact is described.

GSK plc
GSK
± MixedTechnologyrelevance

GSK's quality leader is moderating a fireside chat at a conference on AI in bioprocessing, but no specific business impact is described.

Pfizer Inc
PFE
± MixedTechnologyrelevance

Pfizer's quality leader is participating in a fireside chat at a conference on AI in bioprocessing, but no specific business impact is described.

© 2026 MarketDXNews